08:00 EDT AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024
- Is ABBV a Buy, Before Earnings?
- AbbVie price target raised to $215 from $170 at Citi
- AbbVie, Gedeon Richter collaborate for discovery, development of novel targets
- Regenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
